Avalo Therapeutics AVTX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's operating income?
- Avalo Therapeutics (AVTX) reported operating income of -$20.9M in Q1 2026.
- How has Avalo Therapeutics's operating income changed year-over-year?
- Avalo Therapeutics's operating income decreased by 42.5% year-over-year, from -$14.67M to -$20.9M.
- What is the long-term trend for Avalo Therapeutics's operating income?
- Over 4 years (2021 to 2025), Avalo Therapeutics's operating income has grown at a -2.9% compound annual growth rate (CAGR), from -$82.14M to -$72.93M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.